Leukodystrophy
0
Pipeline Programs
19
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
19 companies ranked by most advanced pipeline stage
Prevail TherapeuticsNY - New York
1 programThe Myelin Disorders Biorepository ProjectN/A1 trial
Active Trials
Human BioSciencesWV - Martinsburg
1 programThe Nosology and Etiology of Leukodystrophies of Unknown CausesN/A1 trial
Active Trials
Genome & CompanyKorea - Suwon
1 programThe Nosology and Etiology of Leukodystrophies of Unknown CausesN/A
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Prevail TherapeuticsThe Myelin Disorders Biorepository Project
Human BioSciencesThe Nosology and Etiology of Leukodystrophies of Unknown Causes
Clinical Trials (2)
Total enrollment: 12,076 patients across 2 trials
The Myelin Disorders Biorepository Project
Start: Dec 2016Est. completion: Dec 203012,000 patients
N/ARecruiting
The Nosology and Etiology of Leukodystrophies of Unknown Causes
Start: Apr 2009Est. completion: Aug 201876 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 12,076 patients
19 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.